Dubai recently hosted a scientific event organised by the American Academy of Pediatrics in collaboration with the Emirates Pediatrics and Neonatal Society. The conference brought together international experts and physicians from the UAE and the wider region to discuss the latest advancements in influenza vaccination.
Dr. Entesar Al Hammadi, President of the Emirates Pediatrics and Neonatal Society, highlighted that the newly introduced influenza vaccine is delivered via a nasal spray, replacing traditional needle injections. This method makes vaccination simpler, faster, and completely painless.
She added that the vaccine is currently approved for individuals aged 2 to 49, with ongoing studies exploring its potential use for other age groups in the future.
Dr. Ahmed Al Hammadi, Infectious Diseases Consultant and Chairman of the Emirates Infectious Disease Society, said the participation of the association in the conference and the introduction of the new vaccine reflect ongoing efforts to raise public awareness about the importance of seasonal influenza vaccination.
He underlined that the initiative seeks to promote safe and effective preventive options, including modern, non-invasive vaccines such as the nasal spray, which provides both safety and convenience. He added that this participation also supports national health strategies aimed at reducing influenza transmission and protecting high-risk populations.
Dr. Eslam El-Baroudy, Professor and Consultant of Paediatrics, and Chief Medical Officer at KidsHeart Centres, described the vaccine’s launch in the region as a major milestone. He noted that introducing a needle-free option can help overcome children’s fear of injections and enhance parental acceptance of vaccination. He added that clinical studies have confirmed the vaccine’s safety and effectiveness.
(Inputs from WAM)
